Details
| Titel in Übersetzung | Immunosuppression after kidney transplantation - future recommendation |
|---|---|
| Originalsprache | Deutsch |
| Seiten (von - bis) | 552-560 |
| Seitenumfang | 9 |
| Fachzeitschrift | Nieren- und Hochdruckkrankheiten |
| Jahrgang | 42 |
| Ausgabenummer | 12 |
| Publikationsstatus | Veröffentlicht - Dez. 2013 |
Abstract
Immunosuppression after kidney transplantation - future recommendation Immunosuppressive therapy after renal transplantation is still a major problem. Whereas an optimal safety profile as transferred to renal graft rejections and especially to the meanwhile frequently diagnosed chronic humoral rejection has to be considered, modern immunosuppressive regimen should also be minimized or attenuated due to severe side effects enhancing the comorbidity and therefore the mortality of renal transplant recipients. Tolerogenic mechanism should be promoted by the diverse immunosuppressives, but defined biomarker for detection of tolerance after kidney transplantation and for use in the clinical practice are currently not yet available. In the article presented here, all efforts to define optimal immunosuppression after renal transplantation are summarized and an outlook in the future is given.
Schlagwörter
- Belatacept, Costimulation blocker, Immunosuppression, Induction of tolerance, Kidney transplantation, Quality of life
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Innere Medizin
- Medizin (insg.)
- Nephrologie
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Nieren- und Hochdruckkrankheiten, Jahrgang 42, Nr. 12, 12.2013, S. 552-560.
Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Forschung › Peer-Review
}
TY - JOUR
T1 - Immunsuppression nach Nierentransplantation
T2 - Was ist die Empfehlung für die Zukunft?
AU - Blume, Cornelia
PY - 2013/12
Y1 - 2013/12
N2 - Immunosuppression after kidney transplantation - future recommendation Immunosuppressive therapy after renal transplantation is still a major problem. Whereas an optimal safety profile as transferred to renal graft rejections and especially to the meanwhile frequently diagnosed chronic humoral rejection has to be considered, modern immunosuppressive regimen should also be minimized or attenuated due to severe side effects enhancing the comorbidity and therefore the mortality of renal transplant recipients. Tolerogenic mechanism should be promoted by the diverse immunosuppressives, but defined biomarker for detection of tolerance after kidney transplantation and for use in the clinical practice are currently not yet available. In the article presented here, all efforts to define optimal immunosuppression after renal transplantation are summarized and an outlook in the future is given.
AB - Immunosuppression after kidney transplantation - future recommendation Immunosuppressive therapy after renal transplantation is still a major problem. Whereas an optimal safety profile as transferred to renal graft rejections and especially to the meanwhile frequently diagnosed chronic humoral rejection has to be considered, modern immunosuppressive regimen should also be minimized or attenuated due to severe side effects enhancing the comorbidity and therefore the mortality of renal transplant recipients. Tolerogenic mechanism should be promoted by the diverse immunosuppressives, but defined biomarker for detection of tolerance after kidney transplantation and for use in the clinical practice are currently not yet available. In the article presented here, all efforts to define optimal immunosuppression after renal transplantation are summarized and an outlook in the future is given.
KW - Belatacept
KW - Costimulation blocker
KW - Immunosuppression
KW - Induction of tolerance
KW - Kidney transplantation
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=84893487472&partnerID=8YFLogxK
U2 - 10.5414/NHX01575
DO - 10.5414/NHX01575
M3 - Übersichtsarbeit
AN - SCOPUS:84893487472
VL - 42
SP - 552
EP - 560
JO - Nieren- und Hochdruckkrankheiten
JF - Nieren- und Hochdruckkrankheiten
SN - 0300-5224
IS - 12
ER -